Bamlanivimab must be administered by intravenous (IV) infusion. Bamlanivimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary. Health care providers must submit a report on all medication errors and ALL SERIOUS ADVERSE EVENTS potentially related to bamlanivimab. See Sections 8 and 9 of the Fact Sheet for Healthcare Providers for reporting instructions below. • The authorized dosage for bamlanivimab is a single intravenous (IV) infusion of 700 mg administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset. • Bamlanivimab is available as concentrated solution and must be diluted prior to administration. • Administer bamlanivimab 700 mg via IV infusion over at least 60 minutes via pump or gravity. • Clinically monitor patients during infusion and observe patients for at least 1 hour after infusion is complete. • Patients treated with bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines. The authorized dosage may be updated as additional data from clinical trials becomes available. For information on clinical trials that are testing the use of bamlanivimab in COVID-19, please see www.clinicaltrials.gov. †Patients with mild COVID-19 illness may exhibit a variety of signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell). They do not have shortness of breath, dyspnea on exertion, or abnormal imaging. Moderate COVID-19 illness is defined as evidence of lower respiratory disease during clinical assessment or imaging, with SpO2 ≥94% on room air at sea level. Source: National Institutes of Health Lilly Bamlanivimab Antibody Playbook | 6 PP-BM-US-0024